ATE389416T1 - Behandlung von knorpelerkrankungen - Google Patents

Behandlung von knorpelerkrankungen

Info

Publication number
ATE389416T1
ATE389416T1 AT01937482T AT01937482T ATE389416T1 AT E389416 T1 ATE389416 T1 AT E389416T1 AT 01937482 T AT01937482 T AT 01937482T AT 01937482 T AT01937482 T AT 01937482T AT E389416 T1 ATE389416 T1 AT E389416T1
Authority
AT
Austria
Prior art keywords
igf
treatment
cartilage
cartilary
diseases
Prior art date
Application number
AT01937482T
Other languages
English (en)
Inventor
Yves Dubaquie
Ellen H Filvaroff
Henry B Lowman
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE389416T1 publication Critical patent/ATE389416T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01937482T 2000-05-16 2001-05-16 Behandlung von knorpelerkrankungen ATE389416T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20449000P 2000-05-16 2000-05-16
US24898500P 2000-11-15 2000-11-15

Publications (1)

Publication Number Publication Date
ATE389416T1 true ATE389416T1 (de) 2008-04-15

Family

ID=26899527

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01937482T ATE389416T1 (de) 2000-05-16 2001-05-16 Behandlung von knorpelerkrankungen

Country Status (8)

Country Link
US (4) US20030069177A1 (de)
EP (1) EP1282437B1 (de)
AT (1) ATE389416T1 (de)
AU (1) AU2001263215A1 (de)
DE (1) DE60133271T2 (de)
DK (1) DK1282437T3 (de)
ES (1) ES2301547T3 (de)
WO (1) WO2001087323A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067144B2 (en) 1998-10-20 2006-06-27 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
EP1099443A1 (de) 1999-11-11 2001-05-16 Sulzer Orthopedics Ltd. Transplantations/Implantatsvorrichtung und ihre Herstellungsmethode
US7387889B2 (en) * 2002-08-22 2008-06-17 Massachusetts Institute Of Technology Measurement of concentrations and binding energetics
ES2405080T3 (es) * 2003-02-26 2013-05-30 Zimmer Orthobiologics, Inc. Preparado para la reparación de un tejido cartilaginoso, en particular de defectos de cartílagos articulares
EP1740190A1 (de) * 2004-03-05 2007-01-10 Synthes GmbH Verwendung eines gemisches für die herstellung eines mittels zur behandlung von defektem oder degeneriertem knorpel in vivo und bei der herstellung von natürlichem knorpelersatz in vitro
WO2005122723A2 (en) * 2004-06-09 2005-12-29 Beth Israel Deaconess Medical Center Compositions and methods that enhance articular cartilage repair
EP1764117A1 (de) 2005-09-20 2007-03-21 Zimmer GmbH Implantat zur Wiederherstellung von Knorpeldefekten und Verfahren zu seiner Herstellung
JP5269612B2 (ja) 2006-02-07 2013-08-21 スパイナルサイト， エルエルシー インビボバイオリアクターを使用する軟骨の修復のための方法および組成物
CL2007002502A1 (es) * 2006-08-31 2008-05-30 Hoffmann La Roche Variantes del factor de crecimiento similar a insulina-1 humano (igf-1) pegilados en lisina; metodo de produccion; proteina de fusion que la comprende; y su uso para tratar la enfermedad de alzheimer.
MX2009006942A (es) * 2006-12-29 2009-11-09 Ipsen Pharma Sas Composiciones farmaceuticas de glp-1.
RU2011118341A (ru) * 2008-10-06 2012-11-20 3-Д Матрикс, Лтд. (Jp) Агент для окклюзии тканей
KR101792032B1 (ko) 2008-12-19 2017-11-02 백스터 인터내셔널 인코포레이티드 Ｔｆｐｉ 억제제 및 사용 방법
DK2547355T3 (en) 2010-03-19 2017-03-20 Baxalta GmbH TFPI INHIBITORS AND METHODS OF USE
ES2653679T3 (es) * 2011-11-09 2018-02-08 Spinalcyte, Llc Fibroblastos dérmicos para el tratamiento de enfermedad discal degenerativa
BR112014022435B1 (pt) 2012-03-21 2023-02-14 Takeda Pharmaceutical Company Limited Inibidores de tfpi e métodos de uso
WO2014004467A1 (en) * 2012-06-25 2014-01-03 The Brigham And Women's Hospital, Inc. Selective cartilage therapy
WO2014008400A2 (en) 2012-07-06 2014-01-09 3-D Matrix, Inc. Fill-finish process for peptide solutions
US10206954B2 (en) 2013-06-19 2019-02-19 Spinalcyte, Llc Adipose cells for chondrocyte applications
US10245299B2 (en) 2014-03-10 2019-04-02 3-D Matrix, Ltd. Autoassembling peptides for the treatment of pulmonary bulla
RU2016139369A (ru) 2014-03-10 2018-04-10 3-Д Матрикс, Лтд. Композиции самоорганизующихся пептидов
BR112016019510A2 (pt) 2014-03-10 2017-10-24 3 D Matrix Ltd esterilização e filtração de composições de peptídeos
US10814038B2 (en) 2016-01-06 2020-10-27 3-D Matrix, Ltd. Combination compositions
JP2021506815A (ja) 2017-12-15 2021-02-22 株式会社スリー・ディー・マトリックス 界面活性ペプチドナノ構造および薬物送達における使用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US3721252A (en) 1971-04-01 1973-03-20 Catheter And Instr Corp Spring guide washer
US4444047A (en) * 1979-06-29 1984-04-24 Vdo Adolf Schindling A.G. Apparatus for determining the fuel consumption of injection internal combustion engines
NO154236C (no) 1979-07-16 1986-08-20 Ciba Geigy Ag Etterbehandling av med flammebeskyttelsesmiddel behandlede, celluloseholdige fibermaterialer med flytende ammoniakk.
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
ATE81779T1 (de) 1985-08-22 1992-11-15 Gropep Pty Ltd Peptidanalogedes insulinaehnlichen wachstumsfaktors-1 bei saeugetieren.
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
SE8505922D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab Construction of an igg binding protein to facilitate downstream processing using protein engineering
ATE90690T1 (de) 1987-04-06 1993-07-15 Celtrix Pharma Menschliche somatomedin-traeger-proteinuntereinheiten und verfahren zu ihrer herstellung.
EP0288451B1 (de) 1987-04-23 1994-08-10 Monsanto Company Sekretion eines dem Insulin ähnlichen Wachstumsfaktors in E. coli
SE8703625D0 (sv) 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
US4876242A (en) 1987-09-21 1989-10-24 Merck & Co., Inc. Human insulin-like growth factor analoges with reduced binding to serum carrier proteins and their production in yeast
US5470828A (en) 1987-12-24 1995-11-28 Gropep Pty. Ltd. Peptide analogs of insulin-like growth factor II
ATE116335T1 (de) 1987-12-24 1995-01-15 Gropep Pty Ltd Peptid-analoge vom insulinähnlichen wachstums- faktor 1 (igf-1) oder faktor 2 (igf-2).
US4988675A (en) 1988-02-05 1991-01-29 Ciba-Geigy Corporation Method for preventing secondary effects
EP0327503B1 (de) 1988-02-05 1993-03-10 Ciba-Geigy Ag Verwendung von IGF I zur Herstellung eines Präparates für die Behandlung von Nierenkrankheiten
DK131988A (da) 1988-03-11 1989-09-12 Erasmus University Igf-bindingsprotein, dna-struktur, der koder for igf-bindingsproteinet og vektor indeholdende denne dna-struktur
US5258287A (en) 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
ATE132164T1 (de) 1988-04-12 1996-01-15 Amgen Boulder Inc Verfahren zur steigerung und zur hemmung der wirkung eines insulinähnlichen wachstumfaktors
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
GB8826451D0 (en) 1988-11-11 1988-12-14 Sandoz Ltd Improvements in/relating to organic compounds
IL92816A0 (en) 1988-12-22 1990-09-17 Biogrowth Inc Recombinant dna molecules,hosts,processes and human somatomedin carrier protein-like polypeptides
CA2007886A1 (en) 1989-01-17 1990-07-17 Marvin L. Bayne Human insulin-like growth factor analogs with reduced binding to 28 k igf binding proteins and their production in yeast
US5514646A (en) 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
US5093317A (en) 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
GB8920381D0 (en) 1989-09-08 1989-10-25 Greater Glasgow Health Board Treatment of insulin-resistant diabetes
SE500903C2 (sv) 1989-12-20 1994-09-26 Atlas Copco Constr & Mining Bergborrningsrigg
ZA9010332B (en) 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
NZ236618A (en) 1990-01-03 1997-06-24 Ciba Geigy Ag Treating and preventing osteoporosis using insulin-like growth factor i (igf i) in conjunction with a bone antiresorptive active compound
US5374620A (en) 1990-06-07 1994-12-20 Genentech, Inc. Growth-promoting composition and its use
US5126324A (en) 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
US5364839A (en) 1990-06-18 1994-11-15 Genetics Institute, Inc. Osteoinductive pharmaceutical formulations
US5593844A (en) 1990-11-19 1997-01-14 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
US5210017A (en) 1990-11-19 1993-05-11 Genentech, Inc. Ligand-mediated immunofunctional hormone binding protein assay method
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
SE9100099D0 (sv) 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
US5206023A (en) 1991-01-31 1993-04-27 Robert F. Shaw Method and compositions for the treatment and repair of defects or lesions in cartilage
US5187151A (en) 1991-02-12 1993-02-16 Genentech, Inc. Use of binding protein with igf-i as an anabolic growth promoting agent
EP1820858B1 (de) 1991-03-01 2009-08-12 Dyax Corporation Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
US5206235A (en) 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
US5202119A (en) 1991-06-28 1993-04-13 Genentech, Inc. Method of stimulating immune response
EP0597033B1 (de) 1991-08-01 1997-04-09 Genentech, Inc. IGF-I zur Verbesserung der neuronale Lage
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
TW267102B (de) 1992-03-13 1996-01-01 Ciba Geigy
SE9201573D0 (sv) 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
HU217543B (hu) 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
NZ255461A (en) 1992-08-20 1996-12-20 Biotechnology & Biolog Science Specific binding molecules for insulin-like-growth-factor-1 (igf-1), antigens capable of generating them and their use in enhancing igf-1 activity
US5273961A (en) 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US5342763A (en) 1992-11-23 1994-08-30 Genentech, Inc. Method for producing polypeptide via bacterial fermentation
CA2132871A1 (en) 1993-01-25 1994-08-04 Alan C. Moses Method for modifying, diagnosing, and screening for igf-i sensitive cell barrier properties
WO1994016723A2 (en) 1993-01-29 1994-08-04 Synergen, Inc. Wound healing composition
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
WO1995017423A1 (en) 1993-12-23 1995-06-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
AU683121B2 (en) 1993-12-23 1997-10-30 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5597700A (en) 1994-04-28 1997-01-28 California Research, Llc Method for detecting free insulin-like growth-factor-binding protein 1 and a test device for detecting the ruptures of fetal membranes using the above method
US5444047A (en) 1994-06-16 1995-08-22 Dipasquale; Gene Treatment of arthritic and post-surgical orthopedic conditions with Insulin-like Growth Factor-I
SE9402331D0 (sv) 1994-07-01 1994-07-01 Pharmacia Ab New use
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5728676A (en) 1994-09-08 1998-03-17 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
US5798337A (en) 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
US5596844A (en) * 1995-02-03 1997-01-28 Kalinowski; Juan R. Foldable portable building
SE9501472D0 (sv) 1995-04-21 1995-04-21 Pharmacia Ab Truncated IGF-I
US5622932A (en) 1995-05-05 1997-04-22 Eli Lilly And Company IGF-1 superagonists
US5741776A (en) 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US5565428A (en) 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
BRPI9608799B8 (pt) 1995-05-26 2019-11-05 Theratechnologies Inc análogo pró-grf -corpo graxo quimérico com aumentada potência biológica, e, formulação farmacêutica.
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US6083913A (en) 1995-06-07 2000-07-04 Glaxo Wellcome Inc. Peptides and compounds that bind to a thrombopoietin receptor
US5958872A (en) 1996-04-01 1999-09-28 Apoptosis Technology, Inc. Active survival domains of IGF-IR and methods of use
CA2224859A1 (en) 1996-04-17 1997-10-23 Amitabh Gaur Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor
WO1998011913A1 (en) 1996-09-16 1998-03-26 Dalhousie University Use of igf-i for the treatment of polycystic kidney disease and related indications
WO1998020036A1 (en) 1996-11-06 1998-05-14 Genentech, Inc. Constrained helical peptides and methods of making same
EP0965596A1 (de) 1996-12-27 1999-12-22 Daiichi Pharmaceutical Co., Ltd. Verfahren zur erhöhung der konzentration freien insulinähnlichen wachstumsfaktors
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
AR012894A1 (es) 1997-06-13 2000-11-22 Lilly Co Eli Formulacion de insulina en solucion estable, su uso para preparar un medicamento y proceso para la preparacion de la misma.
DE19757250A1 (de) 1997-12-22 1999-07-01 Forssmann Wolf Georg Prof Dr Insulin-like growth factor binding protein und seine Verwendung
AU3548999A (en) * 1998-04-03 1999-10-25 Chiron Corporation Use of igfi for treating articular cartilage disorders
ATE303159T1 (de) 1998-10-02 2005-09-15 Celtrix Pharma Null igf zur krebsbehandlung
WO2000023469A2 (en) 1998-10-16 2000-04-27 Musc Foundation For Research Development Fragments of insulin-like growth factor binding protein and insulin-like growth factor, and uses thereof
JP2002535967A (ja) * 1999-01-06 2002-10-29 ジェネンテック・インコーポレーテッド インシュリン様成長因子（ｉｇｆ）ｉ変異体
CA2372393A1 (en) 1999-05-19 2000-11-23 Bassil I. Dahiyat Novel proteins with insulin-like activity useful in the treatment of diabetes
EP1383793B1 (de) 2000-03-29 2011-10-19 DGI BioTechnologies, L.L.C. Agonisten und antagonisten der rezeptoren des insulin und des igf-1

Also Published As

Publication number Publication date
EP1282437A2 (de) 2003-02-12
WO2001087323A2 (en) 2001-11-22
EP1282437B1 (de) 2008-03-19
DE60133271T2 (de) 2009-04-23
US20090011988A1 (en) 2009-01-08
US20030069177A1 (en) 2003-04-10
DE60133271D1 (de) 2008-04-30
DK1282437T3 (da) 2008-06-30
ES2301547T3 (es) 2008-07-01
US20030211992A1 (en) 2003-11-13
US20100130411A1 (en) 2010-05-27
AU2001263215A1 (en) 2001-11-26
WO2001087323A3 (en) 2002-04-11
US8110548B2 (en) 2012-02-07
HK1050321A1 (en) 2003-06-20
US7423017B2 (en) 2008-09-09
US7947650B2 (en) 2011-05-24

Similar Documents

Publication Publication Date Title
ATE389416T1 (de) Behandlung von knorpelerkrankungen
KR970702917A (ko) Lag-3의 가용성 폴리펩타이드 절편 및 생산 방법, 치료 조성물, 항-이디오타입 항체
DE69334266D1 (de) Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate
DE69739035D1 (de) Zusammensetzungen und Methoden zur Behandlung von Infektionen unter Verwendung von Indolicidinanalogen
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
WO2004053059A3 (en) Mitoneet polypeptide from mitochondrial membranes, modulators thereof, and methods of using the same
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
DE60025008D1 (de) Bestimmung von adrenomedullin-bindenden proteinen
ATE286974T1 (de) Therapeutische domänen des von willebrand-faktor
DK0817851T3 (da) DNA, der koder for humant papillomvirus type 18
DE69821793D1 (de) Neuronale verwendungen des bmp-11
DE69433243D1 (de) Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
ATE270328T1 (de) Transgene mäuse, die den leukämie inhibierungsfaktor exprimieren können
ATE432287T1 (de) Peptidfragmente mit den zelltod verhindernder aktivität
WO2002012326A3 (en) Mechanism of conditional regulation of the hypoxia-inducible factor-1 by the von hippel-lindau tumor suppressor protein
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE517629T1 (de) Verwendung eines proteins der crmp familie zur behandlung von krankheiten des immunsystems
PT781341E (pt) Processo para a produção de proteínas recombinantes, plasmídeos e células modificadas
GB9509557D0 (en) PCNA binding substance
ATE439856T1 (de) Verwendung von peptiden, die aus der b beta kette des humanen fibrinogens abgeleitet wurden, zur behandlung von schock
ATE356145T1 (de) Polypeptide zur regenerierung des nervensystems
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
ES2189213T3 (es) Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.
ES2097368T3 (es) Nuevas proteinas inhibidoras de trombina a partir de sanguijuelas terrestres.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1282437

Country of ref document: EP